Clinical effect of glucosamine hydrochloride combined with compound osteopeptide injection for knee osteoarthritis

OBJECTIVE: To investigate the clinical efficacy of glucosamine hydrochloride combined with compound osteopeptide injection for knee osteoarthritis (KOA). METHODS: We retrospectively collected clinical data of 82 patients with KOA admitted to Shandong Weifang People’s Hospital from April 2019 to September 2022. According to the treatment records, 35 patients received an intramuscular injection of compound osteopeptide (control group), and 47 patients received an injection of glucosamine hydrochloride combined with compound osteopeptide (observation group). We compared clinical efficacy, WOMAC scores, inflammatory factor and CD4(+) and CD8(+) levels, and the incidence of adverse reactions between the two groups. RESULTS: The observation group’s total efficacy (95.74%) was significantly higher than the control group’s (80.00%; P<0.05). Treatment led to a significant reduction in WOMAC scores in both groups. In addition, the levels of tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) in the observation group were significantly lower than those in the control group (P<0.05); while the levels of CD4(+) and CD8(+) were significantly higher in the observation group (P<0.05). CONCLUSIONS: Compared with compound osteopeptide injection alone, glucosamine hydrochloride combined with compound osteopeptide injection is more effective for patients with KOA, with improved level of inflammatory factors and immune function.